# GLP-1 for Kids Under 12: What Is Approved and What Is Next

Source: https://www.dietglp.com/blog/glp-1-for-kids/
Published: 2026-11-10
Keywords: glp-1 for kids, glp 1 approved for kids, glp 1 for kids under 12, glp-1 for kids under 12, can kids take glp 1, can children take glp-1, glp-1 approved for children, are glp 1 safe for kids, glp 1 for kids side effects, what glp 1 is approved for kids, wegovy for kids, is wegovy approved for kids, glp 1 pediatric age, glp 1 drugs for kids 2026

**TL;DR:** In the US, no GLP-1 is FDA approved to treat obesity in children under 12. Wegovy injection and Saxenda start at age 12, and a few GLP-1s are approved for type 2 diabetes from age 10. Two trials in kids aged 6 to 11, SCALE Kids (liraglutide) and STEP Young (semaglutide), showed lower BMI than placebo, and the EU now allows Saxenda from age 6. Any use under 12 is a pediatric specialist's call; parents on a GLP-1 themselves can keep their own protein and workouts on track with [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138).

Can kids take a GLP-1? **In the US, no GLP-1 drug is FDA approved to treat obesity in children under 12.** The youngest approved age for weight is 12 (Wegovy injection and Saxenda). For type 2 diabetes, four GLP-1s are approved from age 10. Younger children who get these drugs for weight are getting them off label, and that is happening more often.

GLP-1s for young kids are in the news this week. Families are reading about the FDA's new eye warning for all GLP-1 drugs, and detailed results from Novo Nordisk's STEP Young trial in 6 to 11 year olds are due at ObesityWeek on November 14 to 17, 2026. This guide covers what is approved, what the trials in young children found, and what parents should ask. It is not advice for any one child. That decision belongs to a pediatrician or pediatric obesity specialist.

## What GLP-1 is approved for kids?

Here is where each drug stands for children, based on the current FDA labels we read for our [GLP-1 for teens guide](/blog/glp-1-for-teens/) and on EU decisions.

| Drug (generic) | Youngest US age | US use in kids | Under 12 for obesity? |
|---|---|---|---|
| Wegovy injection (semaglutide) | 12 | Obesity | No (STEP Young trial done, not approved) |
| Saxenda (liraglutide) | 12 | Obesity | Not in the US; EU allows from age 6 |
| Mounjaro (tirzepatide) | 10 | Type 2 diabetes only | No |
| Trulicity (dulaglutide) | 10 | Type 2 diabetes only | No |
| Victoza (liraglutide) | 10 | Type 2 diabetes only | No |
| Bydureon BCise (exenatide) | 10 | Type 2 diabetes only | No |
| Zepbound, Ozempic, Wegovy pill, Foundayo | Adults only | None | No |

So a 10 or 11 year old with type 2 diabetes has on-label GLP-1 options. A child under 12 with obesity but no diabetes does not, in the US.

## GLP-1 for kids under 12: what the trials found

Two large placebo-controlled trials have tested GLP-1 drugs in children aged 6 to under 12. In both, every child also got healthy-eating and activity support.

| Trial | Drug | Children | Length | Main result |
|---|---|---|---|---|
| SCALE Kids (NEJM, 2024) | Liraglutide (Saxenda), daily | 82, aged 6 to 11 | 56 weeks | BMI down 5.8% vs up 1.6% on placebo |
| STEP Young (topline, 2026) | Semaglutide, weekly, max 1.7 or 2.4 mg by weight | 165, aged 6 to under 12 | 68 weeks | 40.4% no longer had obesity vs 0% on placebo |

A few details matter when reading these numbers:

- In STEP Young, more than 85% of the children started with class II or III (severe) obesity.
- The 40.4% figure assumes every child kept taking the drug as planned. The real-world number is usually lower.
- Novo Nordisk said there were no safety concerns for growth or puberty. Detailed side effect rates have not been published yet. We will update this guide after ObesityWeek.
- Update: the full STEP Young results were published in NEJM on November 16, 2026, showing a 13.5% BMI drop vs a 2.7% rise on placebo in the main analysis. Our [STEP Young trial guide](/blog/step-young-trial/) breaks down the numbers and side effects.
- In SCALE Kids, placebo children's BMI went up, which is common in growing kids. That is why BMI, not pounds, is the main measure.

## Can children take GLP-1 in Europe?

Yes, one of them. The European Medicines Agency's committee (CHMP) backed extending Saxenda to children aged 6 to under 12 with obesity (BMI at or above the 95th percentile) who weigh at least 45 kg. It is meant as an add-on to healthy eating and more activity. The EU review, based on the SCALE Kids data, noted that stomach side effects such as nausea were more common in children than in teens and adults. The FDA has not made the same change in the US.

## Why more young kids are getting GLP-1s off label

A study in *Pediatrics* (Orandi and colleagues, published online September 4, 2026) looked at Epic Cosmos health records covering more than 300 million patients. It focused on children aged 8 to 11 with obesity and no diabetes.

| Finding | Number |
|---|---|
| Rise in GLP-1 prescriptions, 2019 to 2026 | About 310-fold |
| Children aged 8 to 11 prescribed a GLP-1 | 20,282 |
| Share with severe obesity | 93.7% |
| Share with at least one other health condition | 65.2% |
| Drugs used | Liraglutide, semaglutide, tirzepatide |

Most of these children had severe obesity and related health problems, which is why some specialists prescribe. The study also found children in higher-income areas were more likely to get a prescription.

## Are GLP-1s safe for kids? Side effects and growth

In the trials, young children mostly had the same side effects as adults: nausea, vomiting, diarrhea and belly pain, usually early and while the dose was going up. What is still unknown is the long-term picture: growth, puberty, bone health and what happens when the drug stops.

Nutrition is a real concern. A September 2026 study in *Childhood Obesity* found that nearly 17% of kids aged 10 to 17 who started a GLP-1 were diagnosed with at least one nutritional deficiency or related problem within a year. Low vitamin D and anemia were the most common. Our guide to [vitamin deficiency on Ozempic](/blog/ozempic-vitamin-deficiency/) explains the adult side of this.

The labels also carry a boxed warning about thyroid tumors, and in November 2026 the FDA asked for a new warning about a rare optic nerve condition (NAION) on all GLP-1 labels. See our [FDA GLP-1 eye warning guide](/blog/fda-glp-1-eye-warning/). Call a doctor right away for sudden vision changes, severe belly pain that will not go away, or signs of dehydration.

## Questions to ask your child's doctor

- Does my child meet the BMI or diabetes criteria on any approved label?
- If this is off label, what evidence supports it for my child's age?
- How will you track growth, puberty, vitamin D and iron?
- Who will set protein and calorie targets for a growing child?
- What is the plan if side effects happen, or if we stop?
- Is there any sign of disordered eating? Our guide to [GLP-1 drugs and eating disorders](/blog/glp-1-medications-and-eating-disorders/) covers why this matters.

Avoid compounded, "research grade" or patch products sold online for children. They are not FDA approved, and dosing mistakes with compounded semaglutide have sent people to the hospital. See [compounded GLP-1 risks](/blog/compounded-glp1/).

## How families can protect a growing body

Kids still need enough protein, calcium, iron and total energy while appetite is low. A pediatric dietitian should set the numbers, since adult GLP-1 targets do not copy over. Habits that help the whole house: protein at every meal, active play or sports most days, regular meals even when not hungry, and water through the day.

Kids copy what adults do. If you are a parent on a GLP-1, [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) gives you one protein target, one 20-minute workout and one Shape Score a day, so your own routine shows the habits you want at home.

## The bottom line

A GLP-1 for kids under 12 is not FDA approved for obesity in the US. The trials in 6 to 11 year olds show BMI drops, the EU now allows Saxenda from age 6, and full STEP Young data is days away. Until the FDA acts, any use in young children is off label and belongs with a pediatric specialist. For parents managing their own GLP-1, [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) keeps protein, a short workout and progress in one daily check-in.

## Sources

- [Novo Nordisk: STEP Young results in children aged 6 to under 12 (2026)](https://www.novonordisk.com/news-and-media/news-and-ir-materials/40-percent-of-children-achieved-BMI-below-obesity-threshold-with-semaglutide.html)
- [Fox CK et al. Liraglutide for children 6 to under 12 years of age with obesity, NEJM 2024](https://doi.org/10.1056/NEJMoa2407379)
- [EMA: Saxenda variation (children 6 to under 12)](https://www.ema.europa.eu/en/medicines/human/variation/saxenda)
- [AJMC: GLP-1 prescribing in young children with obesity rises 310-fold (Pediatrics, Sept 2026)](https://www.ajmc.com/view/glp-1-prescribing-in-young-children-with-obesity-rises-310-fold)
- [PolitiFact: 7 things parents should know about GLP-1s and kids (Oct 2026)](https://www.politifact.com/article/2026/oct/05/glp1-weight-loss-children-obesity-risks-parents/)
- [Childhood Obesity: nutritional deficiencies in pediatric GLP-1 users (Sept 2026)](https://journals.sagepub.com/doi/10.1177/21532176261486979)
- [Wegovy prescribing information (DailyMed)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b)
- [Saxenda prescribing information (openFDA)](https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22SAXENDA%22)


## Frequently asked questions

**Q: Is there a GLP-1 approved for kids?**

A: Not for obesity under age 12 in the US. Wegovy injection and Saxenda are FDA approved for obesity from age 12. Mounjaro, Trulicity, Victoza and Bydureon BCise are approved for type 2 diabetes from age 10. Doctors who prescribe a GLP-1 to a younger child for weight are doing so off label.

**Q: Can a child under 12 take Wegovy?**

A: Wegovy is not FDA approved under age 12. Novo Nordisk tested semaglutide in 165 children aged 6 to under 12 in the STEP Young trial, and full results are due at ObesityWeek, November 14 to 17, 2026. A trial result is not an approval, so talk to a pediatrician before anything else.

**Q: Are GLP-1 drugs safe for kids?**

A: Short-term trials in children aged 6 to 11 found side effects similar to adults, mostly stomach problems like nausea and vomiting. The EU review of Saxenda noted these stomach effects were more common in children than in teens and adults. Long-term data on growth, puberty and bones in young kids is still limited.

**Q: What age can kids take GLP-1?**

A: In the US, the youngest approved age is 10, and only for type 2 diabetes. For obesity, the youngest approved age is 12. In the European Union, Saxenda is now authorized from age 6 for children with obesity who weigh at least 45 kg.

**Q: How many young kids are on GLP-1 drugs?**

A: A Pediatrics study published in September 2026 used Epic Cosmos records and found prescriptions for children aged 8 to 11 with obesity rose about 310-fold from 2019 to mid-2026. In all, 20,282 children in that age group were prescribed liraglutide, semaglutide or tirzepatide, almost all off label.

**Q: Do kids on GLP-1 get nutrient deficiencies?**

A: A September 2026 study in Childhood Obesity reported that nearly 17% of kids aged 10 to 17 who started a GLP-1 were diagnosed with at least one nutritional deficiency or related problem within a year, most often low vitamin D or anemia. That is a reason for regular checkups and a pediatric dietitian.

